BLA 761508 · Regeneron Pharmaceuticals, INC
Pasatru
Garetosmab-Grts · Intravenous
NovelPriority reviewOrphanCDER novel approval, Aug 19, 2026: To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Aug 19, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
3 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 14, 2026.
PASATRU is indicated to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). PASATRU is an activin signaling inhibitor indicated to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). ( 1 )
Mechanism: FOP is caused by gain-of-function mutations in the intracellular domain of activin receptor type 1 (ACVR1, also known as ALK2), a bone morphogenetic protein (BMP) type I receptor that is expressed in many tissues, including skeletal muscle and cartilage. In patients with FOP, mutant ACVR1 is activated by activin A resulting in heterotopic ossification. Garetosmab-grts is a human IgG4 monoclonal antibody that specifically binds to and inhibits signaling by activin A to block the activation of FOP-mutant ACVR1 and reduce the formation and progression of new heterotopic bone lesions.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 19, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelMedication GuideLetter
1 products under this application
- PASATRU · GARETOSMAB-GRTS 300MG/5ML · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Garetosmab" as an intervention, any sponsor and status, largest first.
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06299098 · 1,005 participants · Start Mar 13, 2024 · Primary completion Jun 16, 2026
Drug: Trevogrumab-Part A; Trevogrumab-Part B and Part C and 5 more · For: Obesity
Sites: Anniston, Alabama; Cullman, Alabama; Phoenix, Arizona · 60 sites in all
- A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05394116 · 63 participants · Start Nov 21, 2022 · Primary completion Jul 17, 2025
Drug: Garetosmab; Placebo · For: Fibrodysplasia Ossificans Progressiva
Sites: Los Angeles, California; Nashville, Tennessee; St Leonards, Australia · 22 sites in all
- A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)Pivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07559513 · 18 participants (planned) · Start Feb 2, 2027 · Primary completion Jul 8, 2030
Drug: garetosmab · For: Fibrodysplasia Ossificans Progressiva; FOP
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06970405 · 0 participants · Start May 29, 2025 · Primary completion Jun 8, 2026
Drug: Garetosmab; Matching Placebo · For: Obesity
- Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)Pivotal-lookingWithdrawn
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04577820 · 0 participants · Start Oct 13, 2021 · Primary completion Mar 1, 2022
Drug: garetosmab · For: Fibrodyplasia Ossificans Progressiva (FOP); Heterotopic Ossification (HO)
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Di Rocco M, Forleo-Neto E, Pignolo RJ, et al. · Nat Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial.
Keen R, Dahir KM, McGinniss J, et al. · J Bone Miner Res 2024 · Randomized Controlled Trial, Multicenter Study
- Garetosmab in Fibrodysplasia Ossificans Progressiva: Clinical Pharmacology Results from the Phase 2 LUMINA-1 Trial.
Wang Y, Nguyen JH, de Ruiter RD, et al. · J Clin Pharmacol 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Comparison of PET/CT versus CT only in the assessment of new heterotopic ossification bone lesions in patients with fibrodysplasia ossificans progressiva.
González Trotter D, McGinniss J, Mohammadi K, et al. · Bone 2025 · Randomized Controlled Trial, Comparative Study
- Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Papa R, Rhee S, Delai P, et al. · Lancet 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study.
Vanhoutte F, Liang S, Ruddy M, et al. · J Clin Pharmacol 2020 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Regeneron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.